itching

Pharma

Novartis expands Rhapsido's growing reach in chronic hives

After a first approval in chronic hives, Novartis’ Rhapsido is expanding its reach with a new FDA nod that comes with a notable ‘first’ for the field.

Fraiser Kansteiner Oct 7, 2026 2:27pm

Incyte posts mixed Opzelura results in prurigo nodularis

Mar 10, 2025 11:23am